Examples of ethnicity and geography issues in global clinical trials ...
Examples of ethnicity and geography issues in global clinical trials ...
Examples of ethnicity and geography issues in global clinical trials ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
% per year<br />
Stroke / SSE<br />
Accord<strong>in</strong>g to center based time <strong>in</strong> therapeutic range (cTTR)<br />
Q1: cTTR < 57.1% Q2: cTTR 57.1-65.5%<br />
Q3: cTTR 65.5 – 72.6% Q4: cTTR > 72.6%<br />
2,4<br />
1,8<br />
* Interaction p-value (D 110mg BID vs W.) = 0.90<br />
† Interaction p-value (D 150mg BID vs W.) = 0.20<br />
*Interaction p evaluated by a multivariable approach<br />
with center based TTR as a cont<strong>in</strong>uous variable.<br />
1,2<br />
0,6<br />
W D* D †<br />
110 150<br />
W D* D †<br />
110 150<br />
W D* D †<br />
110 150<br />
W D* D †<br />
110 150<br />
0<br />
Wallent<strong>in</strong> L., et al. Lancet 2010; <strong>in</strong> press.<br />
Q1 Q2 Q3 Q4<br />
Dabigatran etexilate is <strong>in</strong> cl<strong>in</strong>ical development <strong>and</strong> not licensed for<br />
cl<strong>in</strong>ical use <strong>in</strong> stroke prevention for patients with atrial fibrillation
Change language